Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Average Rating of “Moderate Buy” from Analysts

by · The Markets Daily

Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $6.25.

Several brokerages recently issued reports on XERS. Wall Street Zen lowered shares of Xeris Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Oppenheimer lifted their price target on Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research report on Friday, May 9th. HC Wainwright reissued a “buy” rating and set a $8.00 price objective (up from $6.60) on shares of Xeris Biopharma in a research report on Friday, March 7th. Craig Hallum raised their price objective on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research note on Friday, March 7th. Finally, Leerink Partners increased their price target on shares of Xeris Biopharma from $5.00 to $6.00 and gave the company an “outperform” rating in a report on Friday, March 7th.

View Our Latest Analysis on Xeris Biopharma

Insiders Place Their Bets

In other news, insider Kevin Mcculloch purchased 25,000 shares of the stock in a transaction dated Friday, June 13th. The shares were purchased at an average cost of $4.38 per share, with a total value of $109,500.00. Following the acquisition, the insider directly owned 1,708,585 shares of the company’s stock, valued at $7,483,602.30. This represents a 1.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 6.47% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of XERS. R Squared Ltd increased its position in Xeris Biopharma by 27.7% in the first quarter. R Squared Ltd now owns 15,730 shares of the company’s stock worth $86,000 after buying an additional 3,410 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Xeris Biopharma by 4.5% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 80,388 shares of the company’s stock valued at $273,000 after buying an additional 3,447 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in Xeris Biopharma by 31.0% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 16,268 shares of the company’s stock worth $55,000 after buying an additional 3,847 shares during the last quarter. Apollon Wealth Management LLC grew its holdings in Xeris Biopharma by 19.8% during the 1st quarter. Apollon Wealth Management LLC now owns 24,160 shares of the company’s stock valued at $133,000 after purchasing an additional 4,000 shares during the last quarter. Finally, Prudential Financial Inc. raised its holdings in shares of Xeris Biopharma by 23.4% in the fourth quarter. Prudential Financial Inc. now owns 36,945 shares of the company’s stock worth $125,000 after buying an additional 7,000 shares during the period. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Trading Up 1.5%

NASDAQ XERS opened at $4.73 on Friday. Xeris Biopharma has a 1-year low of $2.04 and a 1-year high of $6.07. The firm has a market cap of $739.68 million, a PE ratio of -15.77 and a beta of 0.66. The stock has a 50-day moving average of $4.67 and a 200-day moving average of $4.22.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to the consensus estimate of $57.61 million. As a group, equities research analysts forecast that Xeris Biopharma will post -0.41 earnings per share for the current fiscal year.

About Xeris Biopharma

(Get Free Report

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.

Read More